Guardian Pharmacy surges after earnings beat, guidance boost
Provider posts 57% EPS beat in Q4, swings to $49M full-year profit as EBITDA forecast lifted
Guardian Pharmacy Services shares climbed approximately 6% this week to $33.73 after the long-term care pharmacy provider reported fourth-quarter results that handily exceeded Wall Street expectations and lifted its 2026 outlook.
The company reported quarterly earnings per share of $0.37, beating analyst estimates of $0.235 by 57.4%. Revenue reached $397.6 million, up 12.3% from the prior year and surpassing the $354.1 million consensus forecast. The results marked a significant turnaround for the Atlanta-based company, which swung from a $71 million net loss in 2024 to a $49 million profit in 2025.
Adjusted EBITDA for the fourth quarter surged 53% year-over-year to $39.5 million, underscoring operational leverage in Guardian's business model. Management capitalized on the momentum by raising its 2026 adjusted EBITDA guidance to a range of $120 million to $124 million, up from previous expectations of $115 million to $118 million.
"These results demonstrate the strength of our business model and our ability to execute on our growth strategy," according to the company's official announcement. "Our focus on providing personalized medication management services to the long-term care industry continues to drive meaningful value for our stakeholders."
Guardian Pharmacy Services, which went public on the NYSE, operates as a specialized pharmacy provider serving assisted living and skilled nursing facilities. The company's model focuses on improving patient outcomes through technology-driven medication management and compliance support—services increasingly in demand as the U.S. population ages and regulatory requirements for long-term care facilities intensify.
The stock's rally this week builds on what has been a strong recovery over the past year. Guardian shares traded as low as $18.50 in the past 52 weeks but have since more than doubled, remaining below their 52-week high of $37.43 reached earlier in the year. The company now commands a market capitalization of approximately $2.05 billion.
Analysts maintain a favorable outlook on the stock, with a consensus target price of $35, according to market data. The four analysts covering Guardian all rate it a buy or strong buy, suggesting room for additional upside even after this week's gains. The forward price-to-earnings ratio stands at 29.15, a premium to many traditional pharmacy operators but reflecting the company's growth trajectory and specialized market position.
Institutional investors have taken notice, with approximately 57% of Guardian's shares held by institutions. Insider ownership remains substantial at 38%, providing confidence in management's alignment with shareholders.
The long-term care pharmacy sector faces both opportunities and headwinds. On one hand, demographic trends and increasing acuity levels in nursing homes are driving demand for specialized pharmacy services. On the other, pressure from government payers and rising generic drug costs present ongoing challenges. Guardian's ability to maintain its adjusted EBITDA margin while investing in growth will be a key metric for investors to monitor in coming quarters.
Looking ahead, the raised 2026 EBITDA guidance implies continued growth momentum. If the company can deliver on its new target range, it would represent approximately 43% growth at the midpoint compared to 2025 levels, a pace that would likely support further share price appreciation if executed successfully.